Rare CFTR Mutation Cell Collection Protocol (RARE) (RARE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03161808|
Recruitment Status : Recruiting
First Posted : May 22, 2017
Last Update Posted : December 1, 2021
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target defective CFTR are being evaluated in important clinical trials, but most target the most common CFTR mutation F508del. Many patients with rare CF mutations are not able to participate in those studies. The RARE study is specifically designed for people with CF caused by rare mutations. Eligible rare mutations are listed below:
- CF patients who are homozygous for pre-mature stop codons
CF patients with two mutations in the CFTR gene:
i. One allele must be a F508del ii. The other allele must be a pre-mature stop codon mutation
CF patients with two mutations in the CFTR gene:
i. At least one allele must be a pre-mature stop codon mutation ii. The second allele can be any of the following: G85E, N1303K, R334W, 3849+10kb C->T, 621+1G->T
- CF patients who are homozygous for: G85E, N1303K, R334W, 3849+10kb C->T, or 621+1G->T
This is a multi-site, specimen collection study. Investigators will collect blood, intestinal cells and nasal cells from each participant. Cells from these specimens will be used to test future CFTR modulators to see if they might work for people with study eligible rare mutations. Having cells to test in the lab is an important first step in identifying potential new therapies for people with these mutations.
|Condition or disease|
This is a multi-site, specimen collection study for people with Cystic Fibrosis who have rare mutations. This study is non-interventional so there is no study drug or investigational treatment involved.
- Once a potentially eligible participant is identified (either self-identified or by their CF care center), and the person has expressed interest in participating in the study, the participant will be referred to a participating study site to receive additional information about the study and about travel arrangements (if needed).
- The eligibility criteria are broad and inclusive: Often studies have restrictions around lung function that limit who can participate. The only real restriction for this study rare mutations as defined on the RARE study eligible mutations list.
- Blood, intestinal cells, nasal cells will be collected from all participants.
- Participants will be compensated for the time of the visit and travel expenses will be pre-paid by the study. The study site research coordinator can provide more detail on how much participants will be paid.
- This study is being conducted at six regional sites. Participants may travel to any of the regional study sites to participate, but the participant will need to talk with the research coordinator at the site of their choice to get all of the study details before making a decision to participate. The study site research coordinator will put participants in contact with the travel agency to arrange and pre-pay for travel (including hotel, airline/train arrangements as needed).
Two day study visit
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Rare CFTR Mutation Cell Collection Protocol (RARE)|
|Actual Study Start Date :||October 5, 2017|
|Estimated Primary Completion Date :||December 1, 2023|
|Estimated Study Completion Date :||December 1, 2023|
- The Number of samples collected from cystic fibrosis participants with rare CFTR mutations [ Time Frame: 2-5 year observational period ]CFTR mutations will be confirmed. Once the mutations are confirmed as RARE study eligible mutations, the specimen(s) collected will be expanded, added to a specimen bank and made available to the research community for the evaluation of potential CFTR modulating agents.
- The number of nasal cells collected [ Time Frame: 2-5 year observational period ]Nasal cells will be collected from all participants.
- Number of Blood samples [ Time Frame: 2-5 year observational period ]Blood samples will be collected from all participants
- Number of rectal samples collected [ Time Frame: 2-5 year observational period ]Rectal biopsy samples will be collected from all participants
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161808
|Contact: Heather Y Hathorne, PhDemail@example.com|
|Contact: Justin A Wade, BSfirstname.lastname@example.org|
|United States, Alabama|
|University of Alabama at Birmingham||Recruiting|
|Birmingham, Alabama, United States, 35233|
|Contact: Heather Hathorne, PhD, CCRC 205-639-9568 email@example.com|
|Contact: Justin Y Wade, BS 205-638-9188 firstname.lastname@example.org|
|Principal Investigator: George M Solomon, MD|
|United States, California|
|Lucile S. Packard Children's Hospital||Recruiting|
|Palo Alto, California, United States, 94394|
|Contact: Coleen Dunn 650-736-0388 email@example.com|
|United States, Colorado|
|Children's Hospital Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Allison Keck 720-777-0734 Allison.Keck@childrenscolorado.org|
|United States, Minnesota|
|University of Minnesota Medical Center, Fairview||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: University of Minnesota, Participant Contact University of Minnesota, Participant Contact firstname.lastname@example.org|
|United States, New York|
|Morgan Stanley Children's Hospital of New York||Recruiting|
|New York, New York, United States, 10032|
|Contact: Carmen Liriano 212-305-6265 email@example.com|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: Rachel Sobkowiak 513-803-0762 Rachel.Sobkowiak@cchmc.org|